Bill & Melinda Gates Foundation (BMGF)

BMGF was founded by Bill and Melinda Gates in 2000, and is by far the largest private foundation in the world. BMGF is dedicated to driving innovation in global health and development. It endeavors to solve health problems that plague the poorest populations in the world, including diseases such as tuberculosis, malaria and HIV/AIDS. It has rich experience in cooperating with world-leading biomedical research institutes, international organizations and drug manufacturers, and has already become a key player in catalyzing an effective global health research eco-system.

BMGF provides GHDDI with generous initiation and research funding as well as assistance on institutional development.

Tsinghua University

Established in 1911, Tsinghua University is China’s premier research and training institution. It has a strong foundation in biomedical research in areas such as life science, basic medical science, biomedical engineering, chemistry, chemical engineering, material science, and information technology.

The University invests various resources to support the development of GHDDI, including collaboration on research projects, talents/scientists recruitment, facility development, operation and management.

The School of Pharmaceutical Sciences (SPS) will be the main correspondent collaborator at Tsinghua University, responsible for assisting GHDDI’s further development. Committed to advancing understanding of disease and creating innovative medicine and therapeutics, SPS engages in leading-edge research at the forefront of pharmaceutical sciences ranging from small molecule drugs to biologics, gene therapy, cell therapy, diagnostics and device.

Beijing Municipal Science and Technology Commission (BMSTC)

Beijing Municipal Government has been actively promoting pharmaceutical innovations in small molecule drug, Chinese traditional medicine, biologics, and medical device by providing significant financial, regulatory, and talent development support. Biopharma, in particular, has become a sizable industry sector in recent years.

Adopting a Public-Private Partnership (PPP) model, BMSTC provides grants, policy and institutional development support to GHDDI, which is also facilitated by Beijing Municipal Bureau of Finance, Beijing Municipal Bureau of Civil Affairs, Haidian District Government and Dongsheng Township Government.


California Institute for Biomedical Research (Calibr)

Calibr is an independent not-for-profit institute established in 2012 focusing on translational medicine. It has demonstrated an effective early drug development model through collaborations with researchers across the world while enabling commercial partnerships to bring new candidate therapeutics to the public. Value created from these activities is reinvested in preclinical and clinical research at the institute to create a self-sustaining, ‘evergreen’ model for not-for-profit biomedical research.

Calibr has demonstrated a model of early drug discovery for GHDDI. The Institute also led the effort of acquiring the ReFRAME compound library and provided advice on project portfolios. We have initiated multiple collaboration projects with Calibr.